## (FINL/APPROVED) VIRGINIA BOARD OF PHARMACY

## MINUTES OF PUBLIC HEARING OF SCHEDULING OF CHEMICALS IN SCHEDULE I AND CONFORMING SCHEDULES TO FEDERAL SCHEDULING ACTIONS

Thursday, March 30, 2023 Commonwealth Conference Center Second Floor Board Room 4 Department of Health Professions Perimeter Center 9960 Mayland Drive Henrico, Virginia 23233

CALL TO ORDER:

At 9:06AM, the Board of Pharmacy ("Board") convened two public hearings to consider the scheduling of certain chemicals in Schedule I and conforming drug schedules to recent federal scheduling actions.

PRESIDING:

Dale St.Clair, PharmD, Chairman

MEMBERS PRESENT:

Sarah Melton, PharmD Ling Yuan, PharmD

Patricia Richards-Spruill, RPh

Cheri Garvin, RPh William Lee, DPh Larry Kocot, JD Kristopher Ratliff, 1

Kristopher Ratliff, DPh Wendy Nash, PharmD

STAFF PRESENT:

Caroline D. Juran, RPh, Executive Director James Jenkins Jr., DHP Chief Deputy Director Erin Barrett, JD, DHP Director of Legislative and

Regulatory Affairs

Ryan Logan, RPh, Deputy Executive Director Beth O'Halloran, RPh, Deputy Executive Director Annette Kelley, MS, CSAC, Deputy Executive Director Ellen B. Shinaberry, PharmD, Deputy Executive Director James Rutkowski, Senior Assistant Attorney General

PUBLIC COMMENT

Dr. St.Clair invited members of the public to offer comment on the subject of placing certain chemicals into Schedule I upon recommendation from the Department of Forensic Science and in accordance with subsection D of 54.1-3443. The five chemicals under consideration were:

1. Synthetic compounds.

Sorayah Haden, Executive Assistant

a. N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide (other names: para-fluoro valeryl fentanyl, para-fluoro pentanoyl fentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.

- b.N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (other name: para-fluoroacetyl fentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.
- 2. Compounds expected to have hallucinogenic properties.
- a. 1-[1-(3-fluorophenyl)cyclohexyl]piperidine (other names: 3-fluoro Phencyclidine, 3F-PCP), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
- b. 2-(ethylamino)-2-(2-fluorophenyl)-cyclohexanone (other names: 2-fluoro-2-oxo PCE, 2-fluoro NENDCK), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
- 3. Central nervous system stimulant.
- 2-(3-chlorophenyl)-3-methylmorpholine (other name: 3-chlorophenmetrazine), its salts, isomers (optical, position, and geometric), and salts of isomers.

Robyn Weimer, Chemistry Program Manager, Division of Technical Services, DFS provided public comment in support of the action. No other public comment was offered.

Dr. St.Clair invited members of the public to offer comment on the subject of conforming certain drug schedules to recent federal action in accordance to subsection E of 54.1-3443.

No public comments were offered.

MEETING ADJOURNED

The Public Hearings adjourned at 9:10am.

Caroline D. Juran, Executive Director

6/13/2023

Date